Consensus Grifols, S.A.

Equities

GRF

ES0171996087

Pharmaceuticals

Market Closed - BME Other stock markets 16:44:20 11/07/2025 BST			5-day change	1st Jan Change
11.62 ^EUR	+0.35%		+10.09%	+27.02%

07-10	European Equities Traded in the US as American Depositary Receipts Higher in Thursday Trading	MT
07-10	Grifols, S.A., 2024 Earnings Call, Feb 26, 2025

Evolution of the Average Target: Grifols, S.A.

Evolution of the Target Price: Grifols, S.A.

Changes in Analyst Recommendations: Grifols, S.A.

7561151a75b27066759a31ba1d2e572.3mJnt9UyO_Wb1FaAkj4vwwPhQPVkgtoe1RxJhDEBQbY.qRM_z5lmTbDpuRfGyg9uk1WoKLAiyYV9nmoq52c1cY-cEzTukH1yqqqzHw~c4be3df2074b1e2595a282fe701b3eb4

Analysts' recommendations: Grifols, S.A.

GRIFOLS : Governance and operational improvements are worthy of notice	05-27
GRIFOLS : Invest Securities says undervalued	05-20	CF
GRIFOLS : A healthy Q1 impressed investors	05-13
GRIFOLS : Invest Securities raises its price target	03-04	CF
GRIFOLS : Q4 24: Investors impressed with FCF generation and governance-related announcements	02-27
GRIFOLS : No negative surprise in Q3 was good enough for the market	11-08
GRIFOLS : All eyes on the upcoming takeover bid, despite some normalisation in our estimates	16/10/24
GRIFOLS : Operational improvements continued in the Q2; guidance maintained	31/07/24
GRIFOLS : A strategic move or a ploy to arrest further shareholder wealth erosion?	08/07/24
GRIFOLS : In line Q1 and on track deleveraging; worth a go	15/05/24
GRIFOLS : Factoring in a more moderate earnings recovery; long-term view intact	11/04/24
Invest Securities Keeps Grifols at Buy, Trims PT	01/03/24	MT
GRIFOLS : Market panic following yesterday’s conference call was unwarranted	01/03/24
GRIFOLS : Q4 in line; today’s adverse market reaction means a buying opportunity	29/02/24
GRIFOLS : Grifols accelerates its governance improvements post the short-seller’s allegations	07/02/24
GRIFOLS : Investors not impressed with the conference call; panic opens up attractive entry point	12/01/24
GRIFOLS : Dragged down by a short seller, but the management is ready to respond	10/01/24
GRIFOLS : Delivering on a much-needed deleveraging promise	02/01/24
GRIFOLS : Delivering on a much-needed deleveraging promise	02/01/24
JPMorgan Adjusts Grifols' Price Target to $10.50 From $10, Maintains Neutral Rating	05/12/23	MT
GRIFOLS : Persistently-high interest rate impacts our near-term estimates; fundamentals remain intact	07/11/23
Invest Securities Trims Grifols PT, Maintains Buy Rating	03/11/23	MT
GRIFOLS : Healthy Q3; deleveraging priorities remain on track	03/11/23
GRIFOLS : Good Q2; now all eyes on potential divestments	27/07/23
GRIFOLS : Spanish plasma giant making (gradual) progress	14/06/23

More recommendations

Sector Comparison:

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Financial estimates divergence	Analysts' Target price divergence	Ecart obj. / dr
GRIFOLS, S.A.			+37.33%
CSL LIMITED			+27.15%
REGENERON PHARMACEUTICALS, INC.			+28.32%
SAMSUNG BIOLOGICS CO.,LTD.			+24.7%
UCB			+24.18%
BIOGEN INC.			+28.08%
INNOVENT BIOLOGICS, INC.			+3.28%
ALTEOGEN INC.			+28.7%
INTRA-CELLULAR THERAPIES, INC.	-	-	-
INCYTE CORPORATION			+9.94%
Average			+23.52%
Weighted average by Cap.			+24.88%